273 related articles for article (PubMed ID: 30379158)
1. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
3. Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists.
Jacobson ME; Becker KW; Palmer CR; Pastora LE; Fletcher RB; Collins KA; Fedorova O; Duvall CL; Pyle AM; Wilson JT
ACS Cent Sci; 2020 Nov; 6(11):2008-2022. PubMed ID: 33274278
[TBL] [Abstract][Full Text] [Related]
4. Covalent Polymer-RNA Conjugates for Potent Activation of the RIG-I Pathway.
Palmer CR; Pastora LE; Kimmel BR; Pagendarm HM; Kwiatkowski AJ; Stone PT; Arora K; Francini N; Fedorova O; Pyle AM; Wilson JT
Adv Healthc Mater; 2024 Apr; ():e2303815. PubMed ID: 38648653
[TBL] [Abstract][Full Text] [Related]
5. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
6. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
[TBL] [Abstract][Full Text] [Related]
7. Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs.
Palmer CR; Jacobson ME; Fedorova O; Pyle AM; Wilson JT
Bioconjug Chem; 2018 Mar; 29(3):742-747. PubMed ID: 29350913
[TBL] [Abstract][Full Text] [Related]
8. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
[TBL] [Abstract][Full Text] [Related]
9. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
10. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.
Su L; Pan W; Li X; Zhou X; Ma X; Min Y
Acta Biomater; 2023 Mar; 158():698-707. PubMed ID: 36563773
[TBL] [Abstract][Full Text] [Related]
11. Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles.
Ahmad A; Khan JM; Haque S
Biochimie; 2019 May; 160():61-75. PubMed ID: 30797879
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.
Das M; Shen L; Liu Q; Goodwin TJ; Huang L
Mol Ther; 2019 Mar; 27(3):507-517. PubMed ID: 30545600
[TBL] [Abstract][Full Text] [Related]
14. Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Sayour EJ; Grippin A; De Leon G; Stover B; Rahman M; Karachi A; Wummer B; Moore G; Castillo-Caro P; Fredenburg K; Sarkisian MR; Huang J; Deleyrolle LP; Sahay B; Carrera-Justiz S; Mendez-Gomez HR; Mitchell DA
Nano Lett; 2018 Oct; 18(10):6195-6206. PubMed ID: 30259750
[TBL] [Abstract][Full Text] [Related]
15. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
16. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
[TBL] [Abstract][Full Text] [Related]
17. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Activation of cGAS for Cancer Immunotherapy.
Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
Front Immunol; 2021; 12():753472. PubMed ID: 34899704
[TBL] [Abstract][Full Text] [Related]
19. RIG-I activation is critical for responsiveness to checkpoint blockade.
Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
[TBL] [Abstract][Full Text] [Related]
20. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function.
Johnson LR; Lee DY; Eacret JS; Ye D; June CH; Minn AJ
Cell; 2021 Sep; 184(19):4981-4995.e14. PubMed ID: 34464586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
